

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 1 of 2

Attorney Docket No: 1662.018US1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-98/08539A1	03/05/1998	Rutter, William J., et al.	

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J		"Results from EV01 HIV Vaccine trial, London and Lausanne, June 7th, 2004", (2004), 1 Page	
		ADIS INTERNATIONAL LTD., "HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.", <u>Drugs R D.</u> , 4(4), (2003), 249-53	
		AMARA, R R., "Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques", <u>Virology</u> , 334 (1), (March 30, 2005), 124-33	
		BAYES, M., "Gateways to clinical trials", <u>Methods Find Exp Clin Pharmacol.</u> , 26(4), (May 2004), 295-318	
		BOLESTA, E., "Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens", <u>Virology</u> , 332(2), (February 20, 2005), 467-79	
		FRANCHINI, G., "Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors", <u>Expert Rev Vaccines</u> , 3(4 Suppl), (August 2004), S75-88	
		FRANCHINI, G., et al., "Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses", <u>Nature</u> , 328(6130), (August 6-12, 1987), 539-43	
		HEL, ZDENEK, "Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques", <u>Nature Medicine</u> , 6(10), (October 2000), 1140-1146	
		JIN, XIA, et al., "Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy", <u>Journal of Virology</u> , Vol. 76, No. 5, (2002), 2206-2216	
		LEE, D., "Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160", <u>J Infect Dis.</u> , 190(5), Epub 2004 Jul 29; (September 1, 2004), 903-7	
		MONTEFIORI, D C., "Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines", <u>J Infect Dis.</u> , 190(11), Epub 2004 Oct 28; (December 1, 2004), 1962-9	

EXAMINER

DATE CONSIDERED 08/20/05


Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) & Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 2 of 2

Attorney Docket No: 1662.018US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
J		PERRIN, L., "Therapeutic vaccination in primary HIV infection, the Quest trial", <u>Vaccine</u> , 20(15), (May 6, 2002), 2004-6	
		SADAGOPAL, S., "Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2", <u>Journal of Virology</u> , 79(6), (March 2005), 3243-53	
		SINGH, D K., "A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS", <u>Journal of Virology</u> , 79(6), (March 2005), 3419-28	
		SMITH, J M., "DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime", <u>AIDS Res Hum Retroviruses</u> , 20(12), (December 2004), 1335-47	
		SMITH, J M., "Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses", <u>AIDS Res Hum Retroviruses</u> , 21(2), (February 2005), 140-4	
↓		THIEBOT, HUGUES, et al., "Impact of bone marrow hematopoiesis failure on T-cell generation during pathogenic simian immunodeficiency virus infection in macaques", <u>Blood</u> , 105(6), (March 15, 2005), 2403-2409	

EXAMINER

DATE CONSIDERED

08/21/05

Substitute Disclosure Statement Form (PTO-1449)
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.